
HSCS Stock Forecast & Price Target
HSCS Analyst Ratings
Bulls say
HeartSciences Inc. is enhancing its financial outlook by demonstrating improved earnings per share (EPS) estimates, with a notable upward adjustment from $(4.17) to $(3.76) for FY26, reflecting a better share count. The company is also on a promising trajectory of cost management, leading to an additional increase in EPS estimates from $(3.76) to $(3.28) based on reduced expenses, while expanding its average shares outstanding to 3.2 million. Furthermore, HeartSciences is positioned to capitalize on a significant market opportunity by developing scalable AI-ECG diagnostic solutions, suggesting the potential for recurring revenue through its innovative platform akin to an app store model.
Bears say
HeartSciences Inc. is facing a negative outlook primarily due to a significant lack of visibility regarding the timing of commercial revenues, leading to downward revisions in revenue estimates for fiscal years 2026 and 2027, with projections of only $0.0 million and $0.4 million, respectively. Additionally, while operating expenses were closely aligned with estimates at $2.1 million, the company is encumbered by multiple risks including liquidity concerns, regulatory approval failures, and challenges in product commercialization which could hinder financial stability. Compounding these issues are external factors such as investor sentiment and shifting priorities in healthcare that may negatively impact the company's growth trajectory and overall market performance.
This aggregate rating is based on analysts' research of Heart Test Laboratories Inc and is not a guaranteed prediction by Public.com or investment advice.
HSCS Analyst Forecast & Price Prediction
Start investing in HSCS
Order type
Buy in
Order amount
Est. shares
0 shares